Deals, R&D

The top 10 Alzheimer’s deals tell us a lot about a big change of direction for a disaster-prone field

A decade of disasters in Alzheimer's R&D over the last 10 years — topped by the disastrous and perhaps final fumble on the amyloid beta line by Biogen — has done little to change biopharma's appetite for risky clinical development programs. But it has started to alter the selection of preclinical appetizers mainstream players are ordering these days.

We asked Chris Dokomajilar, the founder of DealForma, to run the numbers on Alzheimer's deals dating back a decade. And what he found may surprise you.

Last year was by far the busiest on record for new Alzheimer's deals, just as big plays by Merck, Lilly and Roche were all headed to the same rocks that have claimed virtually everything floated against this disease in the last decade. Out of the 126 pacts he tracked over the distance, 27 were struck in 2018. And 6 of the top 10 research deals of the decade — calculated by a total of upfronts and milestones — were all inked last year.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,900+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->